Beverly, Massachusetts (PRWEB) June 14, 2016
Velico Medical, Inc., a private medical technology company whose mission is to improve the quality, availability and economics of human platelet and plasma transfusions, was voted “Best in Show” at the 22nd Annual Medtech Investing – Europe conference in Lausanne, Switzerland. The internationally acclaimed investment conference brings together over 150 participants from around the world representing major family offices, venture capital, private equity, angel groups and medical technology companies. Over 40 companies presented at this year’s conference with Velico Medical taking top honors.
“The transformational potential of Velico’s proprietary technologies to save lives, create new standards of care and improve healthcare economics in transfusion medicine was clear to the investors and senior executives present as evidenced by their selection of Velico as ‘Best in Show’ ” stated Bill Skillman, President and CEO of Velico Medical. “Our story is compelling. Velico represents an investment opportunity which we believe will have a significant impact on patients and on the manufacturing and transfusion of human platelets and plasma.”
“We were pleased to have Velico in our presenting company line-up in Lausanne. It’s unusual for a company to receive this level of recognition in their first presentation in a conference of this caliber,” stated Peter Newton, Director of London-based Campden Wealth. “Our hats are off to the Velico team for bringing forward innovative technology which addresses such significant unmet needs for patients requiring platelet and plasma transfusions.”
About Velico Medical
Velico Medical, Inc. is a private medical technology company developing breakthrough technologies expected to transform the quality, availability and economics of platelet and plasma transfusions. Velico’s technologies solve critical unmet needs in transfusing these life-saving blood products in the civilian, first responder and military markets around the world. The technologies underlying Velico’s product candidates are the subject of extensive issued and pending patent applications in countries of commercial consequence to us. Velico’s development efforts are led by seasoned executives and managers, a strong board and an exceptional team of advisors. The US government, through its Biomedical Advanced Research and Development Authority (BARDA), is supporting Velico’s plasma program with a non-dilutive development contract of up to USD $38.5 million.